Navigation Links
Epigentek Develops a New Method of Measuring Global DNA Methylation
Date:9/30/2009

NEW YORK, Sept. 30 /PRNewswire/ -- Epigentek Group Inc. today announced that it released the SuperSense(TM) Methylated DNA Quantification Kit to complete its line of methylated DNA quantification products (http://www.epigentek.com/catalog/dna-methylation-quantification-c-21_48.html). The SuperSense(TM) kit fluorometrically measures global DNA methylation shifts. This new tool complements the company's flagship product and colorimetric version of quantifying methylated DNA, the Methylamp(TM) Global DNA Methylation Quantification Ultra Kit.

Global DNA hypomethylation is likely caused by methyl-deficiency due to a variety of environmental influences and has been proposed as a molecular marker in multiple biological processes such as cancer. It is well demonstrated that the decrease in global DNA methylation is one of the most important characteristics of cancer. Thus the quantification of global methylation in cancer cells provides very useful information for detection and analysis of this disease.

By offering a kit-based method for such quantification, Epigentek makes an improvement over conventional methods (i.e. mass spectrometry, enzymatic degradation and analysis, immunohistostaining), overcoming limitations such as the need for special equipment, long protocols, low sensitivity, and radioactivity.

The new SuperSense(TM) kit is a fluorescence-based assay that can be completed in 3 easy-to-follow steps within 2.5 hours via a convenient 96-well plate format. The kit is extremely sensitive with the detection limit as low as 50 pg of methylated DNA, suitable for quantifying methylated DNA using a very small amount of DNA samples.

Epigentek also simultaneously released a fluorometric version of its EpiQuik(TM) DNA Methyltransferase Activity/Inhibition Assay Kit.

Epigentek's products consistently achieves the fastest speeds and highest results in the epigenetic research kit market. In 2007, Epigentek formed a strategic partnership with Sigma-Aldrich to provide its epigenetic technologies, including DNA methylation and ChIP, to the St. Louis company and to further the studies of epigenetics.

About Epigentek Group Inc.

Epigentek Group Inc. is a biotechnology company that focuses on developing and providing innovative technology and products as a complete and systematic solution for epigenetics-related research and drug discovery. The company, particularly emphasizing speed and effectiveness in its technologies, has developed a comprehensive portfolio of more than 700 proprietary products specifically designed to make assays significantly more simple, fast, convenient and efficient than conventional methods. Visit our website at www.epigentek.com.

    Press Release Contact Information:
    William Lee
    Sales & Marketing Manager
    Epigentek Group Inc.
    1-718-484-3990
    william@epigentek.com

This release was issued through WebWire(R). For more information visit http://www.webwire.com.

SOURCE Epigentek Group Inc.


'/>"/>
SOURCE Epigentek Group Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology news :

1. How schizophrenia develops: Major clues discovered
2. MIT develops tractor beam for cells, more
3. Team of scientists develops non-invasive method to track nerve-cell development in live human brain
4. MBL develops infrastructure and portal for Encyclopedia of Life
5. U of I researcher develops power-packed soy breakfast cereal
6. Scientists discover how TB develops invincibility against only available treatment
7. Europe develops new technologies to boost health of livestock
8. Queens develops safe green decontamination method
9. Carnegie Mellon develops computer model to study cell membrane dynamics
10. Taking a cue from breath fresheners, researcher develops new method for taste testing
11. Engineer develops detergent to promote peripheral nerve healing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2016)... leader in attendance control systems is proud to announce the introduction of fingerprint attendance ... the right employees are actually signing in, and to even control the opening of ... ... ... Photo - ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... Dollar project, for the , Supply and Delivery ... IT Infrastructure , to Decatur ... Identity Management Solutions. Numerous renowned international vendors participated in the ... was selected for the most compliant and innovative solution. The ...
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing ...  3D medical LCD display is the latest premium product recently added to the range ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case ... Denmark detail how a patient who developed lymphedema after being treated for breast cancer ... could change the paradigm for dealing with this debilitating, frequent side effect of cancer ...
Breaking Biology Technology: